Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nanobiotix ( (NBTX) ) just unveiled an update.
On March 25, 2026, Nanobiotix issued a statement addressing recent media speculation about a potential public takeover of the company. The biotechnology group said that, to the best of its knowledge, there is no intention by any party to acquire control of the company and that no process or assessment is underway in that direction.
Management also said it had identified factual inaccuracies in the media report, noting that these claims were inconsistent with its most recent public disclosures. The clarification aims to dampen takeover rumors that could unsettle investors or distort trading in its Paris- and Nasdaq-listed shares, while underscoring the company’s reliance on its formal market communications as the authoritative source of information.
The most recent analyst rating on (NBTX) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
Nanobiotix’s overall stock score is primarily impacted by its poor financial performance, with significant operational losses and financial instability. While technical analysis shows some positive momentum, the negative valuation metrics due to lack of profitability further weigh down the score.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix S.A. is a late-stage clinical biotechnology company pioneering physics-based nanotherapeutic approaches aimed at improving treatment outcomes for cancer and other major diseases. Founded in 2003 and headquartered in Paris with subsidiaries including Cambridge, Mass., it holds more than 30 umbrella patents across platforms targeting oncology, bioavailability and biodistribution, and central nervous system disorders.
The company is dual-listed on Euronext Paris and the Nasdaq Global Select Market, reflecting its focus on both European and U.S. capital markets. Nanobiotix positions itself as a disruptive innovator within oncology and advanced therapeutics, seeking to leverage nanotechnology platforms to address large, underserved patient populations worldwide.
Average Trading Volume: 41,449
Technical Sentiment Signal: Buy
Current Market Cap: $1.43B
For detailed information about NBTX stock, go to TipRanks’ Stock Analysis page.